MAJOR CUSTOMERS	12 Months Ended
Dec. 31, 2024
Risks and Uncertainties [Abstract]
MAJOR CUSTOMERS	NOTE 8 — MAJOR CUSTOMERS For the years ended December 31, 2024 and December 31, 2023, approximately 64% and 66%, respectively, of the Company’s net product revenues were derived from three major customers that are distributors. As of December 31, 2024 and December 31, 2023, accounts receivable due from the three major customers was $3.6 million and $2.6 million, respectively. The largest customer in both years is a domestic medical products and supplies distributor. Although a number of larger infusion customers have elected to consolidate their purchases through one or more distributors in recent years, we continue to maintain strong direct relationships with them. We do not believe that their continued purchase of FREEDOM System products and related supplies is contingent upon the distributor.

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/275/tableOfContent

Name:	us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration